WASHINGTON, Oct. 28 (TNSdock) -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Amgen Inc. from its Office of Prescription Drug Promotion:

* * *

Recipient: Robert Bradway, Chairman and Chief Executive Officer, Amgen Inc., 1 Amgen Center Dr., Thousand Oaks, CA 91320, United States

Issuing Office: The Office of Prescription Drug Promotion (OPDP), United States

WARNING LETTER